This paper is in the following e-collection/theme issue:

Innovations and Technology in Cancer Care (431) Breast Cancer (213) Patient-Reported Outcome Measures (PROMs) (294) Cancer Survivorship (262) Research Instruments, Questionnaires, and Tools (589) Questionnaires and Research Instruments for Cancer Patients (17)

Published on in Vol 7, No 4 (2021): Oct-Dec

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/25776, first published .
Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study

Authors of this article:

Katharina Brusniak1 Author Orcid Image ;   Manuel Feisst2 Author Orcid Image ;   Linda Sebesteny1 Author Orcid Image ;   Andreas Hartkopf3 Author Orcid Image ;   Joachim Graf3, 4 Author Orcid Image ;   Tobias Engler3, 4 Author Orcid Image ;   Andreas Schneeweiss5, 6 Author Orcid Image ;   Markus Wallwiener1 Author Orcid Image ;   Thomas Maximilian Deutsch1 Author Orcid Image
Article Authors Cited by (5) Tweetations (3) Metrics

Journals

  1. Zhuang J, Liu Y, Xu X, Cai Y, Liu M, Chen Z, Yang S, Lin J, Hu Z, Kang M, Lin M, He F. Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma. Journal of Cancer Survivorship 2023;17(6):1769 View
  2. Deutsch T, Pfob A, Brusniak K, Riedel F, Bauer A, Dijkstra T, Engler T, Brucker S, Hartkopf A, Schneeweiss A, Sidey-Gibbons C, Wallwiener M. Machine learning and patient-reported outcomes for longitudinal monitoring of disease progression in metastatic breast cancer: a multicenter, retrospective analysis. European Journal of Cancer 2023;188:111 View
  3. Tsai C, Yang J, Shaverdian N, Patel J, Shepherd A, Eng J, Guttmann D, Yeh R, Gelblum D, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie E, Gomez D, Lee N, Berger M, Robson M, Reis-Filho J, Riaz N, Rudin C, Powell S, Bromberg J, Chen L, Dang C, Das J, Eng J, Girshman J, Gucalp A, Hajj C, Higginson D, Iqbal A, Khan A, LaPlant Q, Mann J, Ng K, Reyngold M, Sanford R, Seidman A, Shah R, Shin J, Sugarman S, Traina T, Tsai C, Wu A, Xu A, Zhi W. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. The Lancet 2024;403(10422):171 View
  4. Chen Z, Zhuang J, Liu M, Xu X, Liu Y, Yang S, Xie J, Lin N, Lai F, He F. Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model. BMC Pulmonary Medicine 2024;24(1) View
  5. Luu T, Dinh D, Tran T, Tran T, Tran H, Pham K, Nguyen H, Jayadevappa R. Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study. PLOS ONE 2024;19(5):e0303011 View